TriangleNCT03106779 · CITED IN SOURCE DOCUMENTS
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2026-08-18
The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Participant flow
Baseline characteristics
Major Molecular Response (MMR) Rate at 24 Weeks
Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)
Complete Cytogenetic Response (CCyR) Rate at Scheduled Time Points
Complete Cytogenetic Response Rate by Scheduled Time Points
Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96
Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points
Time to Major Molecular Response (MMR)
Duration of Major Molecular Response (MMR)
Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR
Duration of Complete Cytogenetic Response (CCyR)
Time to Treatment Failure (TTF)
Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates
Trough Plasma Concentrations for Asciminib
PK Parameter: Cmax for Asciminib
PK Parameter: Tmax for Asciminib
PK Parameter: AUC0-12h for Asciminib
PK Parameter: CL/F for Asciminib
Adverse events
Limitations, agreements, and source contact
Who could take part
- eligibility Criteria
- Inclusion Criteria: Male or female patients with a diagnosis of CML-CP ≥ 18 years of age Patients must meet all of the following laboratory values at the screening visit: * \< 15% blasts in peripheral blood and bone marrow * \< 30% blasts plus promyelocytes in peripheral blood and bone marrow * \< 20% basophils in the peripheral blood * ≥ 50 x 109/L (≥ 50,000/mm3) platelets * Transient prior therapy related thrombocytopenia (\< 50,000/mm3 for ≤ 30 days prior to screening) is acceptable * No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly BCR-ABL1 ratio \> 0.1% IS according to central laboratory at the screening examination for patients intolerant to the most recent TKI therapy Prior treatment with a minimum of 2 prior ATP-binding site TKIs (i.e. imatinib, nilotinib, dasatinib, radotinib or ponatinib) Failure (adapted from the 2013 ELN Guidelines Bacarrani 2013) or intolerance to the most recent TKI therapy at the time of screening * Failure is defined for CML-CP patients (CP at the time of initiation of last therapy) as follows. Patients must meet at least 1 of the following criteria. * Three months after the initiation of therapy: No CHR or \> 95% Ph+ metaphases * Six months after the initiation of therapy: BCR-ABL1 ratio \> 10% IS and/or \> 65% Ph+ metaphases * Twelve months after initiation of therapy: BCR-ABL1 ratio \> 10% IS and/or \> 35% Ph+ metaphases * At any time after the initiation of therapy, loss of CHR, CCyR or PCyR * At any time after the initiation of therapy, the development of new BCR-ABL1 mutations which potentially cause resistance to study treatment * At any time after the initiation of therapy, confirmed loss of MMR in 2 consecutive tests, of which one must have a BCR-ABL1 ratio ≥ 1% IS * At any time after the initiation of therapy, new clonal chromosome abnormalities in Ph+ cells: CCA/Ph+ * Intolerance is defined as: * Non-hematologic intolerance: Patients with grade 3 or 4 toxicity while on therapy, or with persistent grade 2 toxicity, unresponsive to optimal management, including dose adjustments (unless dose reduction is not considered in the best interest of the patient if response is already suboptimal) * Hematologic intolerance: Patients with grade 3 or 4 toxicity (absolute neutrophil count \[ANC\] or platelets) while on therapy that is recurrent after dose reduction to the lowest doses recommended by manufacturer Exclusion Criteria: Known presence of the T315I or V299L mutation at any time prior to study entry Known second chronic phase of CML after previous progression to AP/BC Previous treatment with a hematopoietic stem-cell transplantation Patient planning to undergo allogeneic hematopoietic stem cell transplantation Cardiac or cardiac repolarization abnormality, including any of the following: * History within 6 months prior to starting study treatment of myocardial infarction (MI), angina pectoris, coronary artery bypass graft (CABG) * Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block) * QTcF at screening ≥450 msec (male patients), ≥460 msec (female patients) * Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: * Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia * Concomitant medication(s) with a known risk of Torsades de Pointes per www.crediblemeds.org that cannot be discontinued or replaced 7 days prior to starting study drug by safe alternative medication. * Inability to determine the QTcF interval * Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, pulmonary hypertension) * History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis * History of acute or chronic liver disease * Treatment with medications that meet one of the following criteria and that cannot be discontinued at least one week prior to the start of treatment with study treatment * Moderate or strong inducers of CYP3A * Moderate or strong inhibitors of CYP3A * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 3 days after last dose of ABL001 and one month after last dose of bosutinib. Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception * Female sterilization (have had surgical bilateral oophorectomy (with or without hysterectomy) total hysterectomy or bilateral tubal ligation at least six weeks before taking study treatment). In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment * Male sterilization (at least 6 months prior to screening). The vasectomized male partner should be the sole partner for that subject. * Use of oral, injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. * In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. * Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks before taking study medication. In the case of oophorectomy alone, women are considered post-menopausal and not of child bearing potential only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- healthy Volunteers
- false
- maximum Age
- 100 Years
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Patients were randomized to asciminib 40mg BID
- intervention Names
- Drug: Asciminib
- label
- Asciminib
- type
- EXPERIMENTAL
- description
- Patients were randomized to bosutinib 500mg QD
- intervention Names
- Drug: Bosutinib
- label
- Bosutinib
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Asciminib
- description
- 40 mg tablets was taken orally twice a day (BID)
- name
- Asciminib
- other Names
- ABL001
- type
- DRUG
- arm Group Labels
- Bosutinib
- description
- 500 mg tablets was taken orally once daily (QD)
- name
- Bosutinib
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 233
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
- measure
- Major Molecular Response (MMR) Rate at 24 Weeks
- time Frame
- 24 weeks
- secondary Outcomes
- description
- MMR at 96 weeks was defined as the percentage of participants with MMR at 96 weeks. MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
- measure
- Major Molecular Response (MMR) Rate at 96 Weeks (Key Secondary Endpoint)
- time Frame
- 96 Weeks
- description
- Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
- measure
- Complete Cytogenetic Response (CCyR) Rate at Scheduled Time Points
- time Frame
- at 24, 48, 72, 96, 120 and 144 weeks
- description
- Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \>35 to 65% Ph+ metaphases; Minimal - \>65 to 95% Ph+ metaphases; None - \>95 to 100% Ph+ metaphases.
- measure
- Complete Cytogenetic Response Rate by Scheduled Time Points
- time Frame
- by 24, 48, 72, 96, 120 and 144 weeks
- description
- MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR.
- measure
- Major Molecular Response (MMR) Rate at All Scheduled Data Collection Time Points Except Weeks 24 & 96
- time Frame
- at Weeks 36, 48, 60, 72, 84, 108, 120, 132, 144 & 156
- description
- MMR was defined as a ≥ 3.0 log reduction in BCR-ABL1 transcripts compared to the standardized baseline equivalent to ≤ 0.1% BCR-ABL1/ABL% by international scale (IS) as measured by RQ-PCR. Overall time point has the count indicating participants achieving MMR at any time during the study.
- measure
- Major Molecular Response (MMR) Rate by All Scheduled Data Collection Time Points
- time Frame
- by Weeks 4, 8, 12, 16, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144 & 156, Overall
- description
- Time to MMR was defined as the time from the date of randomization to the date of the first documented MMR.
- measure
- Time to Major Molecular Response (MMR)
- time Frame
- 216 Weeks
- description
- Duration of MMR was defined as the time from the date of first documented MMR to the earliest date of loss of MMR, progression to Accelerated phase (AP) or Blast crisis (BC), or Chronic myeloid leukemia (CML)-related death.
- measure
- Duration of Major Molecular Response (MMR)
- time Frame
- 216 Weeks
- description
- Time to CCyR was defined as the time from the date of randomization to the date of the first documented CCyR.
- measure
- Time to Complete Cytogenetic Response Rate (CCyR) Among Participants Who Achieved CCyR
- time Frame
- 216 Weeks
- description
- Duration of CCyR was defined as the time between date of first documented CCyR and the earliest date of loss of CCyR, progression to AP/BC, or CML-related death for participants in the Cytogenetic Responder Set. The time was censored at the last cytogenetic assessment date on treatment for participants for whom none of the events was reported or last PCR evaluation on treatment indicating MMR.
- measure
- Duration of Complete Cytogenetic Response (CCyR)
- time Frame
- 144 weeks
- description
- TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.
- measure
- Time to Treatment Failure (TTF)
- time Frame
- From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately
- description
- Progression-free survival was defined as the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period), per Kaplan-Meier.
- measure
- Progression Free Survival Per Percentage Event-free Kaplan-Meier Estimates
- time Frame
- From the first dose of treatment up to study completion, up to 5 years
- description
- Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).
- measure
- Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates
- time Frame
- From the first dose of treatment to study completion, up to 5 years
Full study description
- brief Summary
- The purpose of this pivotal study was to compare the efficacy of asciminib (ABL001) with that of bosutinib in the treatment of participants with chronic myeloid leukemia - chronic phase (CML-CP) having previously been treated with a minimum of two prior ATP-binding site tyrosine kinase inhibitors (TKIs).
- detailed Description
- Participants with a diagnosis of CML-CP who had received prior treatment with 2 or more ATP binding site TKIs and were treatment failure (as per guidelines adapted from the 2013 ELN recommendations) or intolerant to the most recent TKI. Participants were randomized in a 2:1 ratio to asciminib 40 mg BID or bosutinib 500 mg QD. Randomization was stratified by major cytogenetic response (MCyR) at screening. Participants with documented treatment failure (as per the 2013 ELN recommendations) while on bosutinib treatment were offered the option to switch to asciminib treatment within 96 weeks after the last patient was randomized to the study.
Source references
- references
- citation
- Mauro MJ, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz N, Dhamal V, Rea D. Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL. Blood Adv. 2025 Aug 26;9(16):4248-4259. doi: 10.1182/bloodadvances.2025016042.
- pmid
- 40334072
- type
- DERIVED
- citation
- Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ. 2023 Jan-Dec;26(1):915-923. doi: 10.1080/13696998.2023.2234776.
- pmid
- 37431294
- type
- DERIVED
- citation
- Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Matsumura I, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Allepuz A, Minami Y. Asciminib vs bosutinib in CML patients pretreated with >/=2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. Cancer Med. 2023 Feb;12(3):2990-2998. doi: 10.1002/cam4.5212. Epub 2022 Sep 27.
- pmid
- 36168187
- type
- DERIVED
- citation
- Li YF, Combes FP, Hoch M, Lorenzo S, Sy SKB, Ho YY. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. Clin Pharmacokinet. 2022 Oct;61(10):1393-1403. doi: 10.1007/s40262-022-01148-9. Epub 2022 Jun 28.
- pmid
- 35764773
- type
- DERIVED
- citation
- Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, Garcia-Gutierrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bedoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
- pmid
- 34407542
- type
- DERIVED
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-d5e378cfadbe35569336
- requested nct id
- NCT03106779
- primary nct id
- NCT03106779
- source kind
- fda_spl_label
- source record id
- e187165a-eb84-4ee5-98b8-d4e777ec7b4a
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- payload sha256
- 03c22585d57e938ca11cc90fec1542388c5af9a80297fd0bc8a09873eaba7199
- payload
- application numbers
- NDA215358
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-d5e378cfadbe35569336
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT03106779
- occurrences
- context exact
- ients with Ph+ CML-CP, previously treated with two or more TKIs was evaluated in the multi-center, randomized, active-controlled, and open-label study ASCEMBL (NCT03106779). In this study, a total of 233 patients were randomized in a 2:1 ratio and stratified according to major cytogenetic response (MCyR) status to receive either
- end
- 4291
- exact text
- NCT03106779
- start
- 4280
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00700.json
- source file sha256
- 24c521d95bd19e54a354ae592997052a3a1b19254da1496b3a98a5e9bac4ed08
- source json pointer
- /results/42/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- e187165a-eb84-4ee5-98b8-d4e777ec7b4a
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 2c51b5ae3b415d4c0016d58eb2c1a6713d147e6cda6338b791d24b33fc53ec60
- spl effective time
- 20251125
- spl set id
- e33001e7-3650-42b1-ae56-cddb5c43aa2b
Preserved source evidence · Not medical advice